Skip to content
Screener

McKesson MCK Return on equity

Discontinued — last reported Q2 '21

Return on equity at other companies

Eli Lilly logo
Eli LillyLLY
107.6%+29.9pp
Cencora logo
CencoraCOR
130.6%-99.8pp
AbbVie logo
AbbVieABBV
89%+32.7pp
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-52.8%-12.7pp
Viatris logo
ViatrisVTRS
-2%-0.9pp
The Oncology Institute, Inc. logo
The Oncology Institute, Inc.TOI
-277.6%-700pp

Other financials

Income statement

See full
Revenue$96.3B+6.0%
Gross profit$4.0B+11.1%
Operating income$2.2B+35.1%
Net income$1.7B+33.5%
EPS (diluted)$13.65+37.6%

Balance sheet

See full
Cash & equivalents$4.0B-33.3%
Total debt$2.3B-74.2%
Total equity-$2.2B-4.7%
Total assets$82.3B+9.6%

Cash flow

See full
Operating cash flow$3.4B-55.8%
CapEx$111.0M-34.3%
Free cash flow$3.3B-56.3%

Valuation

See full
Market cap$100.24B+12.9%
Enterprise value$98.54B+1.3%
P/E21.1×-7.0×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%-0.1pp
Operating margin1.5%+0.3pp
Net margin1.2%+0.3pp
FCF margin1.4%-0.1pp

Returns & leverage

See full
Debt / equity2×—
Current ratio0.9×0.0×

Where this comes from

Calculated from McKesson’s reported figures.

net income/total stockholders equity=36%

Based on trailing twelve months.

The source filing: McKesson’s 10-Q, filed November 2, 2021. Open the filing →

Filed
Nov 1, 2021, 8:00 PM EDT
Fiscal quarter
Q2 FY2022
Calendar quarter
Q3 2021
Accession
0000927653-21-000098

FAQ

What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.